Faculty of Chemistry, M.V. Lomonosov Moscow University, Moscow, Russia.
Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, Moscow, Russia.
PLoS One. 2024 Oct 8;19(10):e0308289. doi: 10.1371/journal.pone.0308289. eCollection 2024.
Analysis of existing mutations of Angiotensin-I-Converting Enzyme (ACE) led us to hypothesize that the carriers of damaging ACE mutations (accompanied by low ACE levels) could be at risk for the development of late-onset Alzheimer's disease (AD).
METHODOLOGY/PRINCIPAL FINDINGS: We quantified blood ACE levels in EDTA-containing plasma from 15 patients with 11 different heterozygous ACE mutations and estimated the effects of these mutations on ACE phenotypes, using a set of mAbs to ACE and two ACE substrates. We confirmed prior observations that the relatively frequent Y215C mutation in the N domain of ACE (present in 1% of the population) is associated with both Alzheimer's disease (AD) and reduced plasma levels of ACE (50% of controls), indicating that it likely results in a transport-deficient protein. In addition, we identified another 4 mutations in both ACE domains (M118T, C734Y, V992M and V997M) which are also associated with decreased ACE levels in the blood, and, thus, could be putative risk factors for late-onset AD. One of these mutations, C734Y, is likely transport-deficient, while the other mutations appear to influence ACE catalytic properties. The precipitation of mutant M118T by mAb 2D1 and ACE mutant C734Y by mAb 3F10 increased 2-3-fold compared to native ACE, and therefore, these mAbs could be markers of these mutations. Also, we identified a mutation I989T, which is associated with increased ACE levels in the blood.
CONCLUSIONS/SIGNIFICANCE: Conducting a systematic analysis of blood ACE levels in patients with ACE mutations holds promise for identifying individuals with low blood ACE levels. Such individuals may be at increased risk for late-onset AD. The patients with transport-deficient ACE mutations may benefit from therapeutic treatment with a combination of chemical and pharmacological chaperones and proteasome inhibitors, as was demonstrated previously using a cell model of the transport-deficient ACE mutation, Q1069R [Danilov et al, PLoS One, 2010].
对血管紧张素转换酶(ACE)现有突变的分析使我们假设,携带破坏性 ACE 突变(同时伴有低 ACE 水平)的载体可能有发展为迟发性阿尔茨海默病(AD)的风险。
方法/主要发现:我们在含有 EDTA 的血浆中定量了 15 名患者的 ACE 水平,这些患者携带 11 种不同的杂合 ACE 突变,并使用一组 ACE 单克隆抗体和两种 ACE 底物来估计这些突变对 ACE 表型的影响。我们证实了先前的观察结果,即在 ACE 的 N 域中相对常见的 Y215C 突变(在人群中约占 1%)与阿尔茨海默病(AD)和 ACE 血浆水平降低(约为对照组的 50%)相关,表明它可能导致转运缺陷蛋白。此外,我们还在 ACE 两个结构域中鉴定出另外 4 种突变(M118T、C734Y、V992M 和 V997M),它们也与血液中的 ACE 水平降低相关,因此可能是迟发性 AD 的潜在危险因素。其中一种突变,C734Y,可能是转运缺陷型,而其他突变似乎影响 ACE 的催化特性。与野生型 ACE 相比,突变 M118T 被单克隆抗体 2D1 沉淀,ACE 突变 C734Y 被单克隆抗体 3F10 沉淀增加了 2-3 倍,因此这些单克隆抗体可能是这些突变的标志物。此外,我们还鉴定出一种与血液中 ACE 水平升高相关的突变 I989T。
结论/意义:对 ACE 突变患者的血液 ACE 水平进行系统分析有望识别血液 ACE 水平低的个体。此类个体可能有较高的迟发性 AD 发病风险。具有转运缺陷 ACE 突变的患者可能受益于化学和药理学伴侣以及蛋白酶体抑制剂的联合治疗,这在先前使用转运缺陷 ACE 突变的细胞模型 Q1069R 时已经得到证明 [Danilov 等人,PLoS One,2010]。